Amgen and the Duke Clinical Research Institute announce initiation of first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 inhibitors (cvMOBIUS) study – the first large-scale real-world study to assess lipid management and the impact of PCSK9 inhibitors on cardiovascular (CV) outcomes in clinical practice. While there is strong […]

Continue Reading

FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease

Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older. “Hope has never been higher for […]

Continue Reading

Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals

The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. […]

Continue Reading

Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to USD 100 million. The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library to develop new treatments for cardiovascular and gynecological diseases. Today, around […]

Continue Reading

Merz to create three independent, customer-focused healthcare businesses to drive growth

Merz, a global, diversified healthcare company, has announced plans for a new business structure that will enable the company to better address customer and patient needs, shorten innovation cycles and capitalize on new market opportunities. The new organizational structure will consist of three independently operating businesses: Merz Aesthetics, Merz Therapeutics and Merz Consumer Care. This […]

Continue Reading

Bayer invests USD 50 Million in eGenesis Series B financing round

eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors, […]

Continue Reading